Global spending on drugs to slow through 2016
(AP) Growth in global spending on medications will slow markedly over the next four years due to a large number of new low-cost generic drugs coming to pharmacies in the U.S. and other developed countries, along with slower increases in what those countries spend on brand-name drugs, according to a new forecast.
But from 2012 through 2016, the pharmaceutical industry will sharply boost its sales in emerging markets including China, India and Russia, according to the report from data firm IMS Health, which collects and analyzes data on pharmaceutical sales around the world.
The company's latest forecast on global medicine sales and trends predicts total spending will rise from about $956 billion in 2011 to just under $1.2 trillion in 2016, based on reported wholesale drug prices. However, IMS estimates the undisclosed rebates and discounts drug companies give to commercial and government prescription plans, a strategy to win more of their business, reduce the actual cost by about 15 percent. That would put total pharmaceutical spending at about $1 trillion in 2016.
Spending will grow at "historically low levels" in the U.S. and might even decline by a percent in Europe, the report says.
The report also says the U.S. share of the world's prescription drug spending will drop from about 41 percent in 2006 and 34 percent last year to 31 percent in 2016. Spending by emerging markets will jump from 14 percent of the total in 2006 to 30 percent in 2016. By 2016, the U.S. will be spending about $892 a year on medicines for an estimated 326 million people, compared to $420 a person in Canada, $121 per person in China and $33 a year per person in India.
"We're going to see the cost of medicines drop dramatically in the U.S." because of all the new generic drugs, said Michael Kleinrock, head of research development at the IMS Institute for Healthcare Informatics.
This year alone, patent expirations will bring new generic competition in the U.S. for nearly 10 blockbusters with $1 billion or more in global annual sales. Those include Singulair for asthma and allergies, Plavix for stroke prevention, high blood pressure drug Diovan, Lexapro for depression and anxiety, osteoporosis treatment Boniva and two medicines for schizophrenia and other serious psychiatric disorders, Seroquel and Geodon.
More than two dozen other big sellers are set to get generic competition from 2013 through 2016. Over six months or so, the prices for generics usually drop by 80 percent or 90 percent from the brand-name price.
Kleinrock noted that about 80 percent of the prescriptions filled in the U.S. now are generics, and he expects that to hit about 85 percent by 2016.
Besides encouraging use of generics, which are generally the only medicines affordable in poor countries, government health programs, particularly in debt-laden European countries, have been pressing drugmakers for lower prices, he said.
More information: www.theimsinstitute.org
Copyright 2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
- Data firm sees 2011 drug sales rising 5-7 percent Oct 07, 2010 | not rated yet | 0
- Americans turn to generic medications in 2010: report Apr 22, 2011 | not rated yet | 0
- Drug prices to plummet in wave of expiring patents Jul 25, 2011 | not rated yet | 0
- Ranbaxy CEO planning expansion in US, elsewhere Jul 10, 2012 | not rated yet | 0
- With new generic rivals, Lipitor's sales halved Dec 20, 2011 | not rated yet | 0
- Motion perception revisited: High Phi effect challenges established motion perception assumptions Apr 23, 2013 | 3 / 5 (2) | 2
- Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update) Apr 02, 2013 | 4.5 / 5 (11) | 5
- The visual system as economist: Neural resource allocation in visual adaptation Mar 30, 2013 | 5 / 5 (2) | 9
- Separate lives: Neuronal and organismal lifespans decoupled Mar 27, 2013 | 4.9 / 5 (8) | 0
- Sizing things up: The evolutionary neurobiology of scale invariance Feb 28, 2013 | 4.8 / 5 (10) | 14
Why is zone 1 in liver more prone to ischemic injury?
6 hours ago Hi, Is it because around central vein, there is only deoxygenated blood from the vein where as in the periphery there is hepatic artery. Also why...
How can there be villous adenoma in colon, if there are no villi there
May 22, 2013 As title suggest. Thanks :smile:
How can there be a term called "intestinal metaplasia" of stomach
May 21, 2013 Hello everyone, Ok Stomach's normal epithelium is simple columnar, now in intestinal type of adenocarcinoma of stomach it undergoes "intestinal...
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013 From pressure-volume curve of the lung and chest wall (attached photo), I don't understand why would the elastic recoil pressure of the lung is...
If you became brain-dead, would you want them to pull the plug?
May 17, 2013 I'd want the rest of me to stay alive. Sure it's a lousy way to live but it beats being all-the-way dead. Maybe if I make it 20 years they'll...
MRI bill question
May 15, 2013 Dear PFers, The hospital gave us a $12k bill for one MRI (head with contrast). The people I talked to at the hospital tell me that they do not...
- More from Physics Forums - Medical Sciences
More news stories
An independent panel of experts on Wednesday recommended US approval of a new Merck sleeping pill called suvorexant, but expressed concerns over the highest dosage and risks of drowsy daytime driving.
Medications 16 hours ago | not rated yet | 0
GlaxoSmithKline PLC says it's starting an unusual collaboration with the U.S. government to develop several antibiotics for both bioterrorism threats and bacterial infections resistant to current medicines.
Medications 18 hours ago | not rated yet | 0
The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...
Medications 23 hours ago | not rated yet | 0
The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.
Medications May 22, 2013 | not rated yet | 0
(Medical Xpress)—Research by U of T Mississauga psychology professor Glenn Schellenberg reveals that two key personality traits – openness-to-experience and conscientiousness—predict better than IQ ...
53 minutes ago | not rated yet | 0 |
Professor Michael Jennings, Deputy Director of the Institute for Glycomics at Griffith University, was part of an international team that discovered the previously unknown pathway of how the bacterium colonizes people.
31 minutes ago | 5 / 5 (1) | 0 |
Scientists at Newcastle University have shed new light on how the brain tunes in to relevant information.
28 minutes ago | 5 / 5 (1) | 0 |
Aggressive forms of bladder cancer involve the protein PODXL – a discovery that could hold the key to improved treatment, according to researchers at Lund University, Uppsala University and KTH in Sweden.
1 hour ago | 5 / 5 (1) | 0
New techniques in imaging of brain activity developed by Jean Gotman, from McGill University's Montreal Neurological Institute, and his colleagues lead to improved treatment of patients suffering from epilepsy. The combination ...
29 minutes ago | not rated yet | 0
Studying the networks of connections in the brains of people affected by schizophrenia, bipolar disease or depression has allowed Dr. Peter Williamson, from Western University, to gain a better understanding of the biological ...
28 minutes ago | not rated yet | 0